CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:00 p.m. EST .
| SEATTLE, April 7, 2021 /PRNewswire/ --CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:00 p.m. EST. The conference will be held in a virtual meeting format.
Presentation details: Event: 20th Annual Needham Virtual Healthcare Conference The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at www.ctibiopharma.com. About CTI BioPharma Corp. We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington. CTI BioPharma Investor Contacts: Maghan Meyers +212-600-1902
SOURCE CTI BioPharma Corp. | ||
Company Codes: NASDAQ-SMALL:CTIC |
View original content to download multimedia:
